Base de dados : MEDLINE
Pesquisa : D26.650.700 [Categoria DeCS]
Referências encontradas : 4365 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 437 ir para página                         

  1 / 4365 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29337676
[Au] Autor:Pajic NZB; Todosijevic MN; Vuleta GM; Cekic ND; Dobricic VD; Vucen SR; Calija BR; Lukic MZ; Ilic TM; Savic SD
[Ad] Endereço:1Department of Pharmaceutical Technology and Cosmetology Faculty of Medicine, University of Banja Luka, 78000 Banja Luka Bosnia and Herzegovina.
[Ti] Título:Alkyl polyglucoside vs. ethoxylated surfactant-based microemulsions as vehicles for two poorly water-soluble drugs: physicochemical characterization and in vivo skin performance.
[So] Source:Acta Pharm;67(4):415-439, 2017 Dec 20.
[Is] ISSN:1846-9558
[Cp] País de publicação:Croatia
[La] Idioma:eng
[Ab] Resumo:Two types of biocompatible surfactants were evaluated for their capability to formulate skin-friendly/non-irritant microemulsions as vehicles for two poorly water-soluble model drugs differing in properties and concentrations: alkyl polyglucosides (decyl glucoside and caprylyl/capryl glucoside) and ethoxylated surfactants (glycereth-7-caprylate/ caprate and polysorbate 80). Phase behavior, structural inversion and microemulsion solubilization potential for sertaconazole nitrate and adapalene were found to be highly dependent on the surfactants structure and HLB value. Performed characterization (polarized light microscopy, pH, electrical conductivity, rheological, FTIR and DSC measurements) indicated a formulation containing glycereth- 7-caprylate/caprate as suitable for incorporation of both drugs, whereas alkyl polyglucoside-based systems did not exhibit satisfying solubilization capacity for sertaconazole nitrate. Further, monitored parameters were strongly affected by sertaconazole nitrate incorporation, while they remained almost unchanged in adapalene-loaded vehicles. In addition, results of the in vivo skin performance study supported acceptable tolerability for all investigated formulations, suggesting selected microemulsions as promising carriers worth exploring further for effective skin delivery of model drugs.
[Mh] Termos MeSH primário: Caprilatos/farmacocinética
Emulsões/farmacologia
Glucosídeos/farmacologia
Veículos Farmacêuticos/farmacocinética
Polissorbatos/farmacologia
Pele/metabolismo
Tensoativos/farmacologia
[Mh] Termos MeSH secundário: Adapaleno/farmacologia
Administração Cutânea
Adulto
Caprilatos/química
Emulsões/química
Glucosídeos/química
Seres Humanos
Imidazóis/farmacologia
Microscopia de Polarização
Veículos Farmacêuticos/química
Polissorbatos/química
Pele/efeitos dos fármacos
Testes de Irritação da Pele
Solubilidade
Espectroscopia de Infravermelho com Transformada de Fourier
Tensoativos/química
Tiofenos/farmacologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Caprylates); 0 (Emulsions); 0 (Glucosides); 0 (Imidazoles); 0 (Pharmaceutical Vehicles); 0 (Polysorbates); 0 (Surface-Active Agents); 0 (Thiophenes); 1L4806J2QF (Adapalene); 72W71I16EG (sertaconazole); Z17H97EA6Y (decyl glucoside)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180117
[St] Status:MEDLINE


  2 / 4365 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29283336
[Au] Autor:Christie C; Madsen SJ; Peng Q; Hirschberg H
[Ad] Endereço:Beckman Laser Institute, University of California, Irvine, 1002 Health Sciences Rd. E, Irvine, CA 92612.
[Ti] Título:Photothermal Therapy Employing Gold Nanoparticle- Loaded Macrophages as Delivery Vehicles: Comparing the Efficiency of Nanoshells Versus Nanorods.
[So] Source:J Environ Pathol Toxicol Oncol;36(3):229-235, 2017.
[Is] ISSN:2162-6537
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Macrophages (Ma) loaded with gold based nanoparticles, which convert near infrared light to heat, have been studied as targeted transport vectors for photothermal therapy (PTT) of tumors. The purpose of the experiments reported here was to compare the efficacy of gold-silica nanoshells (AuNS) and gold nanorods (AuNR) in macrophage mediated PTT. PTT efficacy was evaluated in hybrid glioma spheroids consisting of human glioma cells and either AuNS or AuNR loaded Ma, designated MaNS and MaNR respectivly. Spheroids were irradiated for 10 min. with light from an 810 nm diode laser at irradiances ranging from 0 to 28 W/cm2. PTT efficacy was determined from spheroid growth over a 14-day period. The uptake by Ma of pegylated AuNR (3.9 ± 0.9 %) was twice that of pegylated AuNS, (7.9 ± 0.7 %). Hybrid spheroids consisting of a 5:1 ratio of glioma cells to loaded Ma exhibited significant growth inhibition with MaNS when subjected to irradiances of 7 W/cm2 or greater. In contrast, no significant growth inhibition was observed for the MaNR hybrid spheroids at this 5:1 ratio, even at the highest irradiance investigated (28 W/cm2). Although AuNR were taken up by Ma in larger numbers then AuNS, MaNS were shown to have greater PTT efficacy compared to MaNR for equivalent numbers of loaded Ma.
[Mh] Termos MeSH primário: Neoplasias Encefálicas/terapia
Glioma/terapia
Ouro/administração & dosagem
Hipertermia Induzida/métodos
Macrófagos
Nanopartículas Metálicas/administração & dosagem
Nanoconchas/administração & dosagem
Nanotubos
Fototerapia/métodos
[Mh] Termos MeSH secundário: Animais
Linhagem Celular
Linhagem Celular Tumoral
Seres Humanos
Camundongos
Veículos Farmacêuticos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Pharmaceutical Vehicles); 7440-57-5 (Gold)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171229
[St] Status:MEDLINE
[do] DOI:10.1615/JEnvironPatholToxicolOncol.2017021545


  3 / 4365 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28719374
[Au] Autor:Ip K; Carvalho M; Shan A; Banov D
[Ad] Endereço:Professional Compounding Centers of America (PCCA), Houston, Texas. KIp@pccarx.com.
[Ti] Título:Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox).
[So] Source:Int J Pharm Compd;21(4):322-329, 2017 Jul-Aug.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Budesonide is a corticosteroid that has been shown effective in the treatment of eosinophilic esophagitis, but there are currently no commercial medicines to treat this chronic allergic/immune condition, despite its prevalence in the U.S. Therefore, pharmaceutical compounding is the alternative choice to meet the therapeutic need of eosinophilic esophagitis patients. Two budesonide mucoadhesive oral suspensions (1 mg/10 mL and 2 mg/10 mL) were developed using the compounding vehicle MucoLox, a proprietary mucoadhesive polymer blend that promotes mucosal adhesion. The physical and chemical stability of the oral suspensions was tested over a period of 182 days, at room temperature and refrigerated conditions, in order to determine the corresponding beyond-use date. The physical characterization consisted in observing all samples for color/appearance and odor, and testing for pH and density, whereas the chemical characterization consisted in ultra-performance liquid chromatography assay testing. Both oral suspensions were proven physically and chemically stable, and the ultra-performance liquid chromatography method was proven stability indicating. As a result, the beyond-use date of the budesonide 1-mg/10-mL and 2-mg/10-mL mucoadhesive oral suspensions (MucoLox), in amber plastic bottles, is six months at both room temperature and refrigerated conditions.
[Mh] Termos MeSH primário: Budesonida/química
[Mh] Termos MeSH secundário: Administração Oral
Cromatografia Líquida de Alta Pressão
Composição de Medicamentos
Estabilidade de Medicamentos
Veículos Farmacêuticos
Suspensões
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Pharmaceutical Vehicles); 0 (Suspensions); 51333-22-3 (Budesonide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170719
[St] Status:MEDLINE


  4 / 4365 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28678965
[Au] Autor:Valentim D; Bueno CRE; Marques VAS; Vasques AMV; Cury MTS; Cintra LTA; Dezan E
[Ad] Endereço:Centro Universitário do Distrito Federal - UDF, School of Dentistry, Department of Endodontics, Brasilia, DF, Brazil.
[Ti] Título:Calcium hydroxide associated with a new vehicle: Psidium cattleianum leaf extracts. Tissue response evaluation.
[So] Source:Braz Oral Res;31:e43, 2017 Jul 03.
[Is] ISSN:1807-3107
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to evaluate edemogenic activity and subcutaneous inflammatory reaction induced by Psidium cattleianum leaf extracts associated with Ca(OH)2. Thirty male Wistar rats, split equally into three groups [aqueous extract + Ca(OH)2; ethanolic extract + Ca(OH)2; and propylene glycol + Ca(OH)2], were assessed every 3 h or 6 h (five animals in each period). Under general anesthesia, 0.2 mL of 1% Evans blue per 100 g of body weight was injected into the penile vein and each combination to be evaluated was subcutaneously injected into the dorsal region 30 min thereafter. Edemogenic activity was analyzed by spectrophotometry (λ=630 nm). For inflammatory reaction analysis, 50 rats received four polyethylene tubes (three experimental groups) and an empty tube (control group). The assessments were made at 7, 15, 30, 60, and 90 days, followed by hematoxylin-eosin staining and by the assignment of scores for evaluation of tissue response intensity. Ethanolic extract + Ca(OH)2 yielded the largest edemogenic activity at 3 h. Intergroup differences at 6 h were not significant. The histological analysis showed progressive repair over time (p<0.05) and aqueous and ethanolic extracts produced similar responses to those of the control and Ca(OH)2 + propylene glycol groups. Psidium cattleianum leaf extracts used as Ca(OH)2 vehicles evoked similar tissue response when compared to Ca(OH)2 associated with propylene glycol.
[Mh] Termos MeSH primário: Hidróxido de Cálcio/farmacologia
Extratos Vegetais/farmacologia
Psidium/química
Tela Subcutânea/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Anti-Infecciosos/farmacologia
Portadores de Fármacos
Avaliação Pré-Clínica de Medicamentos
Etanol/farmacologia
Inflamação/tratamento farmacológico
Inflamação/patologia
Masculino
Teste de Materiais
Veículos Farmacêuticos/química
Veículos Farmacêuticos/farmacologia
Folhas de Planta/química
Propilenoglicol/farmacologia
Ratos Wistar
Reprodutibilidade dos Testes
Tela Subcutânea/patologia
Fatores de Tempo
Água/química
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Drug Carriers); 0 (Pharmaceutical Vehicles); 0 (Plant Extracts); 059QF0KO0R (Water); 3K9958V90M (Ethanol); 6DC9Q167V3 (Propylene Glycol); PF5DZW74VN (Calcium Hydroxide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170822
[Lr] Data última revisão:
170822
[Sb] Subgrupo de revista:D; IM
[Da] Data de entrada para processamento:170706
[St] Status:MEDLINE


  5 / 4365 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28403892
[Au] Autor:Qazi F; Shoaib MH; Yousuf RI; Nasiri MI; Ahmed K; Ahmad M
[Ad] Endereço:Department of Pharmaceutics, Faculty of Pharmacy & Pharmaceutical Sciences, University of Karachi, Karachi, 75270, Pakistan.
[Ti] Título:Lipids bearing extruded-spheronized pellets for extended release of poorly soluble antiemetic agent-Meclizine HCl.
[So] Source:Lipids Health Dis;16(1):75, 2017 Apr 12.
[Is] ISSN:1476-511X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Antiemetic agent Meclizine HCl, widely prescribed in vertigo, is available only in immediate release dosage forms. The approved therapeutic dose and shorter elimination half-life make Meclizine HCl a potential candidate to be formulated in extended release dosage form. This study was aimed to develop extended release Meclizine HCl pellets by extrusion spheronization using natural and synthetic lipids. Influence of lipid type, drug/lipid ratio and combinations of different lipids on drug release and sphericity of pellets were evaluated. METHODS: Thirty two formulations were prepared with four different lipids, Glyceryl monostearate (Geleol ), Glyceryl palmitostearate (Precirol ), Glyceryl behenate (Compritol ) and Carnauba wax, utilized either alone or in combinations of drug/lipid ratio of 1:0.5-1:3. Dissolution studies were performed at variable pH and release kinetics were analyzed. Fourier transform infrared spectroscopy was conducted and no drug lipid interaction was found. RESULTS: Sphericity indicated by shape factor (e ) varied with type and concentration of lipids: Geleol (e = 0.891-0.997), Precirol (e = 0.611-0.743), Compritol (e = 0.665-0.729) and Carnauba wax (e = 0.499-0.551). Highly spherical pellets were obtained with Geleol (Aspect ratio = 1.005-1.052) whereas irregularly shaped pellets were formed using Carnauba wax (Aspect ratio = 1.153-1.309). Drug release was effectively controlled by three different combinations of lipids: (i) Geleol and Compritol , (ii) Geleol and Carnauba wax and (iii) Geleol , Compritol and Carnauba wax. Scanning electron microscopy of Compritol pellets showed smooth surface with pores, whereas, irregular rough surface with hollow depressions was observed in Carnauba wax pellets. Energy dispersive spectroscopy indicated elemental composition of lipid matrix pellets. Kinetics of (i) Geleol and Compritol pellets, explained by Korsmeyer-Peppas (R = 0.978-0.993) indicated non-Fickian diffusion (n = 0.519-0.597). Combinations of (ii) Geleol and Carnauba wax and (iii) Geleol , Compritol and Carnauba wax pellets followed Zero-order (R = 0.991-0.995). Similarity test was performed using combination of Geleol and Compritol (i) as a reference. CONCLUSIONS: Matrices for the extended release of Meclizine HCl from extruded-spheronized pellets were successfully formed by using three lipids (Geleol , Compritol and Carnauba wax) in different combinations. The encapsulated pellets of Meclizine HCl can be effectively used for treatment of motion sickness, nausea and vertigo for extended period of time.
[Mh] Termos MeSH primário: Antieméticos/administração & dosagem
Ácidos Graxos/química
Glicerídeos/química
Lipídeos/química
Meclizina/administração & dosagem
Veículos Farmacêuticos/química
Ceras/química
[Mh] Termos MeSH secundário: Administração Oral
Antieméticos/química
Preparações de Ação Retardada/administração & dosagem
Preparações de Ação Retardada/química
Diglicerídeos/química
Composição de Medicamentos
Liberação Controlada de Fármacos
Estabilidade de Medicamentos
Armazenamento de Medicamentos
Seres Humanos
Concentração de Íons de Hidrogênio
Meclizina/química
Microscopia Eletrônica de Varredura
Solubilidade
Espectroscopia de Infravermelho com Transformada de Fourier
Água/análise
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiemetics); 0 (Delayed-Action Preparations); 0 (Diglycerides); 0 (Fatty Acids); 0 (Glycerides); 0 (Lipids); 0 (Pharmaceutical Vehicles); 0 (Waxes); 059QF0KO0R (Water); 18641-57-1 (glyceryl behenate); 230OU9XXE4 (glyceryl monostearate); 3L5TQ84570 (Meclizine); GSY51O183C (precirol); R12CBM0EIZ (carnauba wax)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170726
[Lr] Data última revisão:
170726
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170414
[St] Status:MEDLINE
[do] DOI:10.1186/s12944-017-0466-x


  6 / 4365 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28346204
[Au] Autor:Benischek R
[Ad] Endereço:International Journal of Pharmaceutical Compounding. rlbenischek@aol.com.
[Ti] Título:Restructuring the Art of Health by Pharmacists: Formulation Designs with Oral Vehicles--Teaching Pharmacy Students.
[So] Source:Int J Pharm Compd;21(2):105-108, 2017 Mar-Apr.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Compounding pharmacists, responsible for appropriate preparation of medications, coordinate with other professionals to reach optimal therapeutic options for patients. This review summarizes proprietary oral vehicles or suspensions focusing on available information or updated data from suppliers. Research has advanced methods with revised applications, cutting-edge safety considerations, beyond-use dating provisions for technical assistance, and evidence to review and teach pharmacy students the opportunities in the choices of an oral vehicle. Current marketing, competitive, and scientific trends necessitate that manufacturers shift further to research of product or integrated product mixes to sustain their independence in pharmacies.
[Mh] Termos MeSH primário: Composição de Medicamentos
Educação em Farmácia/métodos
Preparações Farmacêuticas/administração & dosagem
Veículos Farmacêuticos/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oral
Seres Humanos
Preparações Farmacêuticas/química
Veículos Farmacêuticos/química
Estudantes de Farmácia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Pharmaceutical Preparations); 0 (Pharmaceutical Vehicles)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170619
[Lr] Data última revisão:
170619
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE


  7 / 4365 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28301619
[Au] Autor:Pariser D; Bukhalo M; Guenthner S; Kempers S; Shideler S; Gold LS; Tschen E; Berg J; Ferdon MB; Dromgoole S
[Ti] Título:Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis.
[So] Source:J Drugs Dermatol;16(3):234-240, 2017 Mar 01.
[Is] ISSN:1545-9616
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:

BACKGROUND: A novel lotion formulation of halobetasol propionate, 0.05% (HBP Lotion) with enhanced vehicle characteristics of a cream while preserving the ease of use and cosmetic elegance of a lotion has been developed to treat plaque psoriasis. OBJECTIVE: Determine the safety and effectiveness of HBP Lotion in patients with plaque psoriasis. METHODS: Two prospective, randomized, vehicle-controlled clinical studies were conducted in 443 adult subjects with moderate-severe plaque psoriasis. Subjects applied the test article to psoriatic plaques within the treatment area twice daily for 14 days. Efficacy data are based upon treatment "success" defined as those subjects that achieved scores of 0=clear or 1=almost clear with at least a two-grade improvement relative to baseline for an Investigator's Global Assessment (IGA) and clinical signs (plaque elevation, erythema, scaling). Safety data are presented as adverse events and local skin reactions. RESULTS: After two weeks of treatment with HBP Lotion, 44.5% of the HBP Lotion treated subjects in each study achieved (a) treatment "success" (ie, an IGA score of 0=clear or 1=almost clear and >2 grade improvement compared to baseline) and (b) a notable reduction in plaque elevation, erythema, scaling, and pruritus. In contrast, only 6.3% and 7.1% of VEH subjects in Studies 1 and 2, respectively, achieved treatment success and the reduction of disease related signs was materially lower. Statistically, at day 15 in both Phase 3 studies, treatment success with HBP Lotion was superior to VEH (P less than 0.001). From a safety perspective the outcomes were in general unremarkable with similar findings in the HBP Lotion and VEH treatment groups. CONCLUSIONS: The results demonstrate the safety and effectiveness of HBP Lotion in the treatment of plaque psoriasis. Furthermore, this novel HBP lotion formulation is also distinguished by its moisturization qualities and ease of use.

J Drugs Dermatol. 2017;16(3):234-240.

.
[Mh] Termos MeSH primário: Clobetasol/análogos & derivados
Glucocorticoides/uso terapêutico
Psoríase/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Cutânea
Adulto
Clobetasol/administração & dosagem
Clobetasol/efeitos adversos
Clobetasol/uso terapêutico
Método Duplo-Cego
Feminino
Glucocorticoides/administração & dosagem
Glucocorticoides/efeitos adversos
Seres Humanos
Masculino
Veículos Farmacêuticos/administração & dosagem
Estudos Prospectivos
Índice de Gravidade de Doença
Creme para a Pele
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Glucocorticoids); 0 (Pharmaceutical Vehicles); 9P6159HM7T (halobetasol); ADN79D536H (Clobetasol)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170317
[St] Status:MEDLINE


  8 / 4365 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28301614
[Au] Autor:Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
[Ti] Título:A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
[So] Source:J Drugs Dermatol;16(3):197-204, 2017 Mar 01.
[Is] ISSN:1545-9616
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:

BACKGROUND: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Treatment options focus on relieving symptoms, reducing inflammation, induration, and scaling, and controlling the extent of the disease. Topical corticosteroids are the mainstay of treatment, however long-term safety remains a concern, particularly with the more potent formulations. Combination therapy with a corticosteroid and tazarotene may improve psoriasis signs at a lower corticosteroid concentration providing a superior safety profile. OBJECTIVE: To investigate the efficacy and safety of a once-daily application of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ) lotion in comparison with its monads and vehicle in subjects with moderate-to-severe plaque psoriasis. METHODS: Multicenter, randomized, double-blind, vehicle-controlled Phase 2 study in moderate or severe psoriasis (N=212). Subjects randomized (2:2:2:1 ratio) to receive HP/TAZ, individual monads, or vehicle, once-daily for 8 weeks. Efficacy assessments included treatment success (defined as at least a 2-grade improvement from baseline in the IGA score and a score of 'Clear' or 'Almost Clear'), and impact on individual signs of psoriasis (erythema, plaque elevation, and scaling) at the target lesion. Safety and treatment emergent adverse events (TEAEs) were evaluated throughout. RESULTS: HP/TAZ lotion demonstrated statistically significant superiority over vehicle as early as 2 weeks. At week 8, 52.5% of subjects had treatment success compared with 33.3%, 18.6%, and 9.7% in the HP (P=0.033), TAZ (P less than 0.001), and vehicle (P less than 0.001) groups, respectively. HP/TAZ lotion was superior to its monads and vehicle in reducing the psoriasis signs of erythema, plaque elevation, and scaling at the target lesion. At week 8, a 2-grade improvement in IGA was achieved by 54.2% of subjects for erythema, 67.8% for plaque elevation, and 64.4% for scaling. Most frequently reported TEAEs were application site reactions, and were more likely associated with the tazarotene component. Side effects such as skin atrophy were rare. CONCLUSIONS: HP/TAZ lotion was consistently more effective than its monads or vehicle in achieving treatment success and reducing psoriasis signs of erythema, plaque elevation, and scaling at the target lesion. Safety data were consistent with the known safety profile of halobetasol propionate and tazarotene, and did not reveal any new safety concerns with the combination product.

J Drugs Dermatol. 2017;16(3):197-204.

.
[Mh] Termos MeSH primário: Clobetasol/análogos & derivados
Fármacos Dermatológicos/uso terapêutico
Glucocorticoides/uso terapêutico
Ácidos Nicotínicos/uso terapêutico
Psoríase/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Cutânea
Clobetasol/administração & dosagem
Clobetasol/efeitos adversos
Clobetasol/uso terapêutico
Fármacos Dermatológicos/administração & dosagem
Fármacos Dermatológicos/efeitos adversos
Método Duplo-Cego
Combinação de Medicamentos
Feminino
Glucocorticoides/administração & dosagem
Glucocorticoides/efeitos adversos
Seres Humanos
Masculino
Ácidos Nicotínicos/administração & dosagem
Ácidos Nicotínicos/efeitos adversos
Veículos Farmacêuticos/administração & dosagem
Índice de Gravidade de Doença
Creme para a Pele
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Drug Combinations); 0 (Glucocorticoids); 0 (Nicotinic Acids); 0 (Pharmaceutical Vehicles); 81BDR9Y8PS (tazarotene); 9P6159HM7T (halobetasol); ADN79D536H (Clobetasol)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170317
[St] Status:MEDLINE


  9 / 4365 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28266909
[Au] Autor:Massarsky A; Abdel A; Glazer L; Levin ED; Di Giulio RT
[Ad] Endereço:1 Nicholas School of the Environment, Duke University , Durham, North Carolina.
[Ti] Título:Exposure to 1,2-Propanediol Impacts Early Development of Zebrafish (Danio rerio) and Induces Hyperactivity.
[So] Source:Zebrafish;14(3):216-222, 2017 Jun.
[Is] ISSN:1557-8542
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The use of electronic cigarettes (e-cigarettes) is increasing as an alternative to tobacco burning cigarettes; however, their safety remains to be fully determined. The long-term effects of e-cigarettes are unknown, including the effects of maternal e-cigarette use on pre- and postnatal development. Additional research on the safety of e-cigarettes is needed. Especially useful would be information from high- and moderate-throughput economic model systems. This study investigates the effects of 1,2-propanediol, which was identified as the main component of e-cigarette liquid, on early development of zebrafish (an in vivo high-throughput model system that was recently proposed for the study of tobacco cigarette and e-cigarette toxicity). Zebrafish embryos were exposed to 1.25% or 2.5% 1,2-propanediol from 6 to 72 h post-fertilization (hpf). We show that exposure to 1,2-propanediol did not significantly affect mortality. Hatching success was significantly lower in 2.5% 1,2-propanediol-exposed embryos at 48 hpf, but at 72 hpf no significant differences were noted. Moreover, exposure to 1,2-propanediol reduced growth and increased the incidence of string heart, pericardial edema, and yolk sac edema. Most importantly, developmental exposure to 1.25% 1,2-propanediol caused hyperactive swimming behavior in larvae. This study demonstrates that 1,2-propanediol has adverse impacts on early development in zebrafish.
[Mh] Termos MeSH primário: Comportamento Animal/efeitos dos fármacos
Embrião não Mamífero/efeitos dos fármacos
Hipercinese/epidemiologia
Propilenoglicol/toxicidade
Peixe-Zebra/crescimento & desenvolvimento
[Mh] Termos MeSH secundário: Animais
Modelos Animais de Doenças
Edema/induzido quimicamente
Edema/epidemiologia
Cardiopatias/induzido quimicamente
Cardiopatias/epidemiologia
Hipercinese/induzido quimicamente
Larva/efeitos dos fármacos
Larva/crescimento & desenvolvimento
Veículos Farmacêuticos
Natação/fisiologia
Teratogênios/toxicidade
Saco Vitelino/efeitos dos fármacos
Peixe-Zebra/embriologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Pharmaceutical Vehicles); 0 (Teratogens); 6DC9Q167V3 (Propylene Glycol)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170308
[St] Status:MEDLINE
[do] DOI:10.1089/zeb.2016.1400


  10 / 4365 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28257952
[Au] Autor:Hernandes MR; Moraes LC; Ribeiro EB; Fagundes DL; Honorio-França AC; França EL
[Ad] Endereço:Department of Parasitology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Institute of Biological and Health Science - Federal University of Mato Grosso, Barra do Garças, MT, Brazil. Electronic address: botoaraguaia@gmail.com.
[Ti] Título:In vitro immunomodulatory effects of microemulsions with levamisole delivery systems on blood phagocytes interacting with Giardia lamblia.
[So] Source:Parasitol Int;66(3):299-304, 2017 Jun.
[Is] ISSN:1873-0329
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Giardiasis is one of the main parasites that infect the gastrointestinal tract of humans, affecting hundreds of millions of people worldwide, particularly in developing countries. Antiparasitics administered to treat giardiasis are inefficient in 20% of the cases, usually because of parasite resistance and side effects. In this scenario, microemulsions are a promising pharmaceutical alternative as carriers of molecules with therapeutic action that stimulate the immune system. METHODS: The study evaluated the effects of a microemulsion delivery system with levamisole hydrochloride on the functional activity of MN phagocytes incubated with G. lamblia. RESULTS: The microemulsion formulated was incorporated with levamisole hydrochloride using distilled water, caprylic/capric triglyceride-Polymol 812®, Sorbitan Oleate-Span 80®, Polysorbate 80 - Tween 80® and 1-butanol. The activity of the microemulsion was analyzed by phagocytosis rate, microbicidal activity, apoptosis rate and intracellular calcium concentration. Phagocytosis rate, microbicidal activity and apoptosis index increased in the microemulsion treatment. The results suggest that the microemulsion improves the therapeutic efficacy of levamisole, increasing the functional activity of phagocytes. CONCLUSIONS: The microemulsion with a levamisole delivery system is therefore an efficient alternative for treating giardiasis, acting as an immunomodulator that probably causes fewer side effects than conventional drugs.
[Mh] Termos MeSH primário: Giardia lamblia/efeitos dos fármacos
Levamisol/administração & dosagem
Levamisol/farmacologia
Fagócitos/efeitos dos fármacos
Fagócitos/imunologia
[Mh] Termos MeSH secundário: Animais
Apoptose/efeitos dos fármacos
Emulsões/química
Giardia lamblia/imunologia
Giardíase/tratamento farmacológico
Seres Humanos
Imunomodulação/efeitos dos fármacos
Técnicas In Vitro
Tamanho da Partícula
Fagócitos/parasitologia
Fagocitose/efeitos dos fármacos
Veículos Farmacêuticos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Emulsions); 0 (Pharmaceutical Vehicles); 2880D3468G (Levamisole)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170510
[Lr] Data última revisão:
170510
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170305
[St] Status:MEDLINE



página 1 de 437 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde